Harmony Biosciences Holdings, Inc.

What they do

Harmony in-licenses, develops and commercializes neuroscience therapies in the United States. Its approved product WAKIX is a first-in-class histamine H3 receptor antagonist/ inverse agonist for narcolepsy, licensed from Bioprojet, and it is the only FDA-approved narcolepsy treatment not scheduled as a controlled substance by the DEA. Beyond WAKIX, the company is developing next-generation pitolisant formulations (Pitolisant GR and HD), the orexin-2 receptor agonist BP-205 (BP1.15205), and rare epilepsy candidates EPX-100 and EPX-200 acquired with Epygenix Therapeutics.

Revenue drivers

• WAKIX (pitolisant) - narcolepsy — The company's only approved product and effectively all reported revenue. WAKIX is approved for excessive daytime sleepiness (EDS) in adults and pediatric patients six years and older, and for cataplexy in adults (October 2020), pediatric patients (February 2026). Q2 2026 net product revenue was $261.3 million, up 30% year over year, with estimated average patients of approximately 8,950.
• Pipeline - orexin-2 agonist BP-205 — No revenue today. BP-205 (BP1.15205) is an orexin-2 receptor agonist sublicensed from Bioprojet and originally discovered by Teijin Pharma; Phase 1 single ascending dose data were reported in August 2026, with multiple ascending dose data expected in Q4 2026 and Phase 2 trials targeted to begin in mid-2027.
• Pipeline - next-generation pitolisant — No revenue today. Pitolisant GR (gastro-resistant) had its NDA accepted in July 2026 with a target PDUFA date of April 1, 2027; Pitolisant HD (high-dose) is targeted for Phase 3 topline data in 2027 and a PDUFA date in 2028.
• Pipeline - rare epilepsy and cell therapy — No revenue today. EPX-100 (clemizole hydrochloride) is in two Phase 3 registrational trials for Dravet Syndrome and Lennox-Gastaut Syndrome, and EPX-200 is pre-IND for developmental and epileptic encephalopathies. A 2025 CiRC Biosciences collaboration covers discovery-stage cell replacement candidates CBS105 and CBS104.

Recent performance

Q2 2026 WAKIX net revenue was $261.3 million, up 30% year over year, and the company called it record quarterly revenue. Estimated average patients were approximately 8,950, an increase of 450 versus the prior quarter. Full-year 2025 revenue was $868.5 million with net income of $158.7 million and diluted EPS of $2.71, and operating cash flow was $348.2 million. At June 30, 2026, the company reported $549.8 million in cash and equivalents, $373.8 million in total liabilities, $134.0 million of long-term debt, and $999.2 million of shareholder equity.

Strategy

Management's stated priority is to keep growing WAKIX, reiterating 2026 net revenue guidance of $1.0 billion to $1.04 billion, while expanding the commercial organization. In Q2 2026 the company fully deployed expanded field sales, remote sales, field reimbursement and patient outreach teams and launched an online portal and revised reimbursement support process. The pipeline strategy centers on BP-205 as a potential best-in-class orexin-2 agonist, alongside next-generation pitolisant formulations and rare epilepsy assets. Harmony describes the pipeline as self-funded by WAKIX cash flow, with no new equity or debt raise disclosed in the provided materials. The company also broadened into cell replacement therapy through the June 2025 CiRC Biosciences collaboration.

Risks

• Single-product concentration — The 10-K states the business is substantially dependent on WAKIX, its only approved product, so any decline in WAKIX sales or market acceptance would directly hit revenue and financial condition.
• Licensing dependence on Bioprojet — Core pitolisant intellectual property rights come from the 2017 and 2022 license agreements with Bioprojet, and termination or loss of those rights would impair development and commercialization.
• Reimbursement and pricing pressure — The 10-K notes that failure to obtain and sustain adequate third-party payer coverage and reimbursement for WAKIX would adversely affect sales, and cites increased pricing pressure and policy changes as factors.
• Pipeline and regulatory uncertainty — The 10-K describes the FDA approval process as costly, lengthy and inherently unpredictable, and states that the company may not succeed in expanding pitolisant to additional indications or in developing the orexin, epilepsy and next-generation pitolisant programs.

Outlook

Management reiterates 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion and expects Phase 1 MAD data for BP-205 in Q4 2026, a Phase 1b study in sleep-deprived healthy volunteers beginning in Q3 2026 with data expected in early 2027, and Phase 2 trials in multiple CNS indications starting in mid-2027. For pitolisant, the Pitolisant GR NDA has a target PDUFA date of April 1, 2027, while Pitolisant HD is targeted for Phase 3 topline data in 2027 and a PDUFA date in 2028.